Contact
searchSearch
HMP Global
Login

Acute Lymphoblastic Leukemia Specialty Channel

Acute Lymphoblastic Leukemia
Specialty Channel
Matthew Connor, MD
Conference Coverage
Evolving Strategies for the Treatment of Acute Lymphoblastic Leukemia
01/22/2026
Matthew Connor, MD
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted...
01/22/2026
Oncology
Matthew Connor, MD
Conference Coverage
IL18-Armored CAR T-Cell Therapy Produces Deep and Sustained Responses for Heavily Pretreated B-Cell Acute Lymphoblastic Leukemia
01/16/2026
Matthew Connor, MD
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported...
01/16/2026
Oncology
Alexandra Gomez Arteaga, MD
Videos
Exploring the Optimal Role of Transplant for Patients with Acute Lymphoblastic Leukemia
10/14/2025
Alexandra Gomez Arteaga, MD
Alexandra Gomez Arteaga, MD, shares insights into which patients with acute lymphoblastic leukemia should be considered for transplant, including those failing to meet MRD negativity or who have a higher genomic risk.
Alexandra Gomez Arteaga, MD, shares insights into which patients with acute lymphoblastic leukemia should be considered for transplant, including those failing to meet MRD negativity or who have a higher genomic risk.
Alexandra Gomez Arteaga, MD,...
10/14/2025
Oncology
Elias Jabbour, MD
Conference Coverage
Utilizing Immunotherapies for Optimal Treatment of Ph-Positive Acute Lymphoblastic Leukemia
06/29/2025
Elias Jabbour, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.
At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.
At the 2025 Great Debates in...
06/29/2025
Oncology
Shira Dinner, MD
Conference Coverage
Benefits of Chemotherapy Plus Allogeneic Stem Cell Transplantation as Treatment Strategy for Ph-Positive ALL
06/28/2025
Shira Dinner, MD
Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.
Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.
Shira Dinner, MD, debates the...
06/28/2025
Oncology
Quiz
Autologous Hematopoietic Stem Cell Transplant for Ph-Negative ALL
05/27/2025
In a retrospective study assessing autologous hematopoietic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, which patient subgroup demonstrated superior leukemia-free survival at 5...
In a retrospective study assessing autologous hematopoietic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, which patient subgroup demonstrated superior leukemia-free survival at 5...
In a retrospective study...
05/27/2025
Oncology
News
Autologous Hematopoietic Stem Cell Transplant Shows Safety for Late Treatment Intensification for Ph-Negative ALL
05/16/2025
Emily Estrada
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem...
05/16/2025
Oncology
Quiz
Efficacy of Inaticabtagene Autoleucel for B-ALL
05/05/2025
What was the overall response rate observed at month 3 following treatment with inaticabtagene autoleucel in a phase 2 trial among patients with R/R B-cell acute lymphoblastic leukemia?
What was the overall response rate observed at month 3 following treatment with inaticabtagene autoleucel in a phase 2 trial among patients with R/R B-cell acute lymphoblastic leukemia?
What was the overall response...
05/05/2025
Oncology
News
Dasatinib Plus CAR T-Cell Therapy Shows Encouraging Efficacy for Patients With Newly Diagnosed Ph-Positive ALL
04/29/2025
Emily Estrada
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly...
04/29/2025
Oncology
Quiz
Inaticabtagene Autoleucel Therapy for R/R B-ALL
04/21/2025
Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?
Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?
Regarding the durability of...
04/21/2025
Oncology
News
Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
03/25/2025
Emily Estrada
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel...
03/25/2025
Oncology

News

Matthew Connor, MD
Conference Coverage
Evolving Strategies for the Treatment of Acute Lymphoblastic Leukemia
01/22/2026
Matthew Connor, MD
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted emerging ASH 2025 data showing earlier use of CAR T-cell therapy and novel antigen targets for acute lymphoblastic leukemia, along with ponatinib-based frontline strategies.
Matthew Connor, MD, highlighted...
01/22/2026
Oncology
Matthew Connor, MD
Conference Coverage
IL18-Armored CAR T-Cell Therapy Produces Deep and Sustained Responses for Heavily Pretreated B-Cell Acute Lymphoblastic Leukemia
01/16/2026
Matthew Connor, MD
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported that IL18-armored CD19 CAR T-cells produced deep, durable remissions with manageable toxicity among heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia in a phase 1 trial.
Matthew Connor, MD, reported...
01/16/2026
Oncology
Alexandra Gomez Arteaga, MD
Videos
Exploring the Optimal Role of Transplant for Patients with Acute Lymphoblastic Leukemia
10/14/2025
Alexandra Gomez Arteaga, MD
Alexandra Gomez Arteaga, MD, shares insights into which patients with acute lymphoblastic leukemia should be considered for transplant, including those failing to meet MRD negativity or who have a higher genomic risk.
Alexandra Gomez Arteaga, MD, shares insights into which patients with acute lymphoblastic leukemia should be considered for transplant, including those failing to meet MRD negativity or who have a higher genomic risk.
Alexandra Gomez Arteaga, MD,...
10/14/2025
Oncology
Elias Jabbour, MD
Conference Coverage
Utilizing Immunotherapies for Optimal Treatment of Ph-Positive Acute Lymphoblastic Leukemia
06/29/2025
Elias Jabbour, MD
At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.
At the 2025 Great Debates in Hematologic Malignancies meeting, Elias Jabbour, MD, participated in a debate on the optimal regimen for treating Ph-positive ALL, highlighting the benefits of utilizing immunotherapies.
At the 2025 Great Debates in...
06/29/2025
Oncology
Shira Dinner, MD
Conference Coverage
Benefits of Chemotherapy Plus Allogeneic Stem Cell Transplantation as Treatment Strategy for Ph-Positive ALL
06/28/2025
Shira Dinner, MD
Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.
Shira Dinner, MD, debates the benefits of chemotherapy followed by allogeneic stem cell transplantation among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia at the 2025 Great Debates in Hematologic Malignancies.
Shira Dinner, MD, debates the...
06/28/2025
Oncology
News
Autologous Hematopoietic Stem Cell Transplant Shows Safety for Late Treatment Intensification for Ph-Negative ALL
05/16/2025
Emily Estrada
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem...
05/16/2025
Oncology
News
Dasatinib Plus CAR T-Cell Therapy Shows Encouraging Efficacy for Patients With Newly Diagnosed Ph-Positive ALL
04/29/2025
Emily Estrada
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly...
04/29/2025
Oncology
News
Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
03/25/2025
Emily Estrada
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel...
03/25/2025
Oncology
News
Durability and Tolerability of Obecabtagene Autoleucel CAR-T Therapy for R/R B-Cell Acute Lymphoblastic Leukemia
02/07/2025
Emily Estrada
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with...
02/07/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology

Interactive Features

Quiz
Autologous Hematopoietic Stem Cell Transplant for Ph-Negative ALL
05/27/2025
In a retrospective study assessing autologous hematopoietic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, which patient subgroup demonstrated superior leukemia-free survival at 5...
In a retrospective study assessing autologous hematopoietic stem cell transplantation for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, which patient subgroup demonstrated superior leukemia-free survival at 5...
In a retrospective study...
05/27/2025
Oncology
Quiz
Efficacy of Inaticabtagene Autoleucel for B-ALL
05/05/2025
What was the overall response rate observed at month 3 following treatment with inaticabtagene autoleucel in a phase 2 trial among patients with R/R B-cell acute lymphoblastic leukemia?
What was the overall response rate observed at month 3 following treatment with inaticabtagene autoleucel in a phase 2 trial among patients with R/R B-cell acute lymphoblastic leukemia?
What was the overall response...
05/05/2025
Oncology
Quiz
Inaticabtagene Autoleucel Therapy for R/R B-ALL
04/21/2025
Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?
Regarding the durability of remission achieved with inaticabtagene autoleucel therapy among patients with R/R B-ALL in a phase 2 trial, what was the median duration of remission reported?
Regarding the durability of...
04/21/2025
Oncology
Quiz
Efficacy of Imatinib vs Dasatinib Prophylaxis Among Patients With Philadelphia-Positive ALL Following ASCT
04/02/2024
04/02/2024
Oncology
Quiz
R/R Pre-B ALL Treatment With Mini-Hyper CVD Chemotherapy Plus Inotuzumab Ozogamicin With or Without Blinatumomab
08/01/2023
True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.
True or False: A treatment regimen of low-intensity mini-hyper CVD plus inotuzumab and blinatumomab demonstrated improved survival outcomes among patients with R/R Philadelphia chromosome-negative CD22-positive pre-B ALL.
True or False: A treatment...
08/01/2023
Oncology
Quiz
Quiz: Use of Inotuzumab Ozogamicin Induction Therapy for De Novo Acute B-Lymphoblastic Leukemia
03/01/2023
True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.
True or False: 3 cycles of inotuzumab ozogamicin induction therapy showed promising remission rates in patients aged >55 years with de novo acute B-lymphoblastic leukemia, according to findings from a recent trial.
True or False: 3 cycles of...
03/01/2023
Oncology
Quiz
Use of Blinatumomab During Consolidation for High-Risk Ph-Negative B-Cell Precursor ALL
03/01/2023
True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.
True or False: The use of blinatumomab during consolidation for high-risk Philadelphia chromosome negative B-Cell precursor acute lymphoblastic leukemia was associated with reduced relapse rates, according to findings from a recent trial.
True or False: The use of...
03/01/2023
Oncology
Quiz
Quiz: ASCT From Matched Sibling Donors vs Matched Unrelated Donors in Adult High-Risk ALL
10/05/2022
True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.
True or False: Allogeneic hematopoietic stem cell transplantations from matched sibling donors and matched unrelated donors yielded similar long-term outcomes for patients with BCR-ABL-negative ALL.
True or False: Allogeneic...
10/05/2022
Oncology
Quiz
Quiz: Complete Remission Rate Among Patients With R/R B-Cell ALL With Anti-CD19 CAR T-Cell Therapy
08/23/2022
True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.
True or false: The complete remission rate was higher among patients with relapsed/refractory B-cell ALL with lower (rather than with higher) tumor burden receiving treatment with anti-CD19 CAR T-cell therapy.
True or false: The complete...
08/23/2022
Oncology
Quiz
Quiz: Patients With ALL Are More Likely to Receive Salvage Chemotherapy After Treatment With Which Prior Therapy?
08/05/2022
True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...
True or False: Findings from the phase 3 INO-VATE trial revealed that patients with relapsed/refractory ALL who received inotuzumab ozogamicin were less likely to receive subsequent salvage therapy than those who received standard...
True or False: Findings from the...
08/05/2022
Oncology

Recent News

News
Autologous Hematopoietic Stem Cell Transplant Shows Safety for Late Treatment Intensification for Ph-Negative ALL
05/16/2025
Emily Estrada
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem cell transplantation demonstrated relative safety for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia, according to a recent study.
Autologous hematopoietic stem...
05/16/2025
Oncology
News
Dasatinib Plus CAR T-Cell Therapy Shows Encouraging Efficacy for Patients With Newly Diagnosed Ph-Positive ALL
04/29/2025
Emily Estrada
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia, dasatinib plus sequential CD19-CD22 CAR T-cell therapy demonstrated improved outcomes and high rates of complete molecular remission.
For patients with newly...
04/29/2025
Oncology
News
Inaticabtagene Autoleucel Demonstrates Efficacy and Tolerability for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
03/25/2025
Emily Estrada
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia showed efficacy and durability in a phase 2 clinical trial.
Inaticabtagene autoleucel...
03/25/2025
Oncology
News
Durability and Tolerability of Obecabtagene Autoleucel CAR-T Therapy for R/R B-Cell Acute Lymphoblastic Leukemia
02/07/2025
Emily Estrada
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with relapsed/refractory B-cell acute lymphoblastic leukemia, obecabtagene autoleucel anti-CD19 CAR-T therapy showed promising durability and tolerability, according to a recent study.
For patients with...
02/07/2025
Oncology
News
FDA Approves Oral Formulation of Imatinib for Patients With Certain Leukemias and Gastrointestinal Tumors
11/25/2024
Stephanie Holland
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced liquid formulation of imatinib for patients with certain leukemias and gastrointestinal tumors to increase dosing accuracy.
The FDA has approved an advanced...
11/25/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Blinatumomab Added to Consolidation Chemotherapy Improves Overall Survival Among Patients in MRD-Negative Remission From B-Cell Precursor ALL
08/14/2024
Amber Denham
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study, the addition of blinatumomab to consolidation chemotherapy for adult patients in measurable residual disease-negative remission from B-cell precursor acute lymphoblastic leukemia significantly improved overall...
According to a phase 3 study,...
08/14/2024
Oncology
News
FDA Grants Approval to Blinatumomab Consolidation Therapy for CD19-Positive Philadelphia Chromosome-Negative B-cell Precursor ALL
06/21/2024
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to blinatumomab for adult and pediatric patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multi-phase chemotherapy.
The FDA granted approval to...
06/21/2024
Oncology
News
Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL
04/09/2024

Jordan Kadish

Jordan Kadish
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
According to a phase 1/2 trial,...
04/09/2024
Oncology
News
Allogeneic Stem Cell Transplantation in First Complete Remission for Patients With Philadelphia Chromosome-Positive ALL
04/01/2024

Jordan Kadish

Jordan Kadish
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who received allogeneic stem cell transplantation in the first complete remission demonstrated superior survival outcomes compared with patients who did not undergo...
Patients with Philadelphia...
04/01/2024
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use